Hudson Bay Capital Management LP Editas Medicine, Inc. Transaction History

Hudson Bay Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $388,600 - $528,200	-20,000 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$18.19 - $31.79 $1.64 Million - $2.86 Million	-90,000 Reduced 81.82%	20,000 $455,000
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $276,500 - $383,900	10,000 Added 10.0%	110,000 $3.5 Million
Q2 2018 Aug 13, 2018	BUY	$31.4 - $41.01 $1.26 Million - $1.64 Million	40,000 Added 66.67%	100,000 $3.58 Million
Q4 2017 Feb 12, 2018	SELL	$21.89 - $31.34 $875,600 - $1.25 Million	-40,000 Reduced 40.0%	60,000 $1.84 Million
Q3 2017 Nov 13, 2017	BUY	$15.81 - $24.01 $1.58 Million - $2.4 Million	100,000	100,000 $2.4 Million

240

56.5M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.